About
Axor Biosystems was founded to improve biological reaction purification and QC processes by 100x - to help accelerate breakthroughs in diagnoses and treatment of cancer, dementia, senescence, genetic diseases …
Embedded Files
Motivation
Motivation
The explosion of genomic and proteomic data led to a data analysis bottleneck. The data analysis challenge was mitigated by the introduction of ML and AI tools which created a new challenge, processing 10-100x more samples to fill in the shortfall of data.
Existing sample and reaction purification and QC piplelines are unable to scale to the 100x increase in number of samples needed to feed the high-throughput data generation and analysis pipelines. The complex workflows, high overhead costs and inefficiencies of traditional sample preparation processes are contributing to a worsening bottleneck - a barrier choking data generation and decreasing the flow of scientific breakthroughs.
We decided to focus on this challenge with pie-in-the-sky product requirements:
A single system, eliminating the fragmented processes requiring multiple instruments and protocols. The single system needs to perform the required reaction, separate the products of the reaction, quantitate the constituents of the reaction products and determine the molecular weight. All in one box.
A single consumable, replacing the large volume of reagents, cartridges, beads, tips, troughs, plates, tubes needed today.
At least 10x faster than the current methods
At least 10x cheaper
The task was daunting till we stumbled upon an elegantly simple solution. Embedding the purification and QC processes within the confines of a single laboratory microplate. We could achieve our goal of a 100x improvement over existing sample prep processes.
Founding team
Founding team
Brett Anderson, the CTO, and Abizar Lakdawalla, the CEO, worked together at Apton Biosystems to develop an ultra-high throughput Next Generation Sequencing & Proteomics platform based on a novel sub-diffraction imaging technology invented by Bryan Staker, co-founder and CTO of Apton.
The co-founders have >25 years of experience in developing, building and launching systems & applications in genomics such as microfluidic reaction processors, next generation sequencing systems, infectious disease detection panels, liquid biopsies for cancer and sepsis, cell & gene therapy products, and single-molecule nanopore-based sequencing at Apton Biosystems, IDbyDNA, Proxeom, Resilience, Synthego, Ultima Genomics, Illumina and Thermo Fisher Scientific.
Brett Anderson, PhD
Brett Anderson, PhD
CTO
Brett is a single-molecule bioengineer by training with a strong background in developing firmware and software for complex life sciences tools, from single-molecule nanopore sequencing to brain implant monitors.
He likes integrating real-time imaging to steer biomolecules through meandering channels under the influence of hard-to-resist electrical currents.
Abizar Lakdawalla, PhD
Abizar Lakdawalla, PhD
CEO
Abizar had worked on microfluidic devices for Sanger sequencing before helping develop and launch Next Generation sequencing platforms and assays.
He likes conjuring up solutions to challenging problems while tacking in a 20 knot wind.
Page updated
Report abuse